The decisions that determine Phase 2 timing are made, or missed, in the first two quarters after the IND opens.
White Paper
IND Ready Is Not Phase 2 Ready
Related Resources
All Resources
case-study
Syner-G Partners with Leading Supplier in Life Sciences to Build Out New cGMP Compliant Facilities
Read More
case-study
Mobilizing Pharmaceutical Technology Transfers to a Contract Development and Manufacturing Organization (CDMO)
Read More
post
CFD Applications in Design of Manufacturing Processes and Facilities
Read More
post
How Regulatory Strategy Drives Innovation in Biopharma
Read More
Let's move from science to success.
Let’s Talk